Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin added to sulfonylurea ± metformin in type 2 diabetes
2016-002826-35Phase 3Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sotagliflozin 400 mg arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 26. Started Feb 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-002826-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002826-35.